On October 5, 2022 KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs, reported that it will be presenting data on its product candidate VET3-TGI at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC) (Free SITC Whitepaper), taking place November 8-12, 2022 in Boston, Massachusetts (Press release, KaliVir Immunotherapeutics, OCT 5, 2022, View Source [SID1234621752]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VET3-TGI is based on KaliVir’s unique Vaccinia Enhanced Template (VET) platform, capable of generating potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. VET3-TGI incorporates modifications granting the expression of CXCR3, IL-12 and a TGF-β inhibitor, allowing for efficient trafficking to the tumor, activation of anti-tumor immune responses and inhibition of immunosuppressive activity.